Amanda Ely is CEO of the Children’s HIV Association (CHIVA), an organization that provides support to children living with HIV in the United Kingdom and Ireland and their families.
Amanda Ely is CEO of the Children’s HIV Association (CHIVA), an organization that provides support to children living with HIV in the United Kingdom and Ireland and their families.
Transcript
Can you discuss the difficulty involved with telling a child born with HIV they have the virus?
This is one of those issues that we have done work in other countries, and we attend events and conferences and things that we meet professionals in other countries doing similar work, and everybody has this experience. It’s one of those really interesting issues that crosses into different cultures and societies in a really similar way.
One of the key problems is the ongoing impact of HIV-related stigma, which means that for many families, it’s very difficult to talk about HIV because they’re very worried about the consequences of that and people in communities, unfortunately, still reacting badly to the knowledge that there’s HIV in a family with an individual, and the fears of rejection and discrimination around that. In some settings, of course, this can be really serious actually in terms of sort of threats of harm, etc.
But nonetheless, no matter what the context, these fears tend to persist. So that means telling a child about their HIV is even more complicated than it would be if you were telling the child about another health condition, which similarly affected them; for example, diabetes or something, which is a lifelong condition requiring treatment but without the stigma.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen